Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19288569 | 0.90 | GRIN2D (0.33) | MAPTSIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL12515038 | 0.89 | MAPT (0.35) | MAPTSIGMAR1 | |
| SCHEMBL20467389 | 0.79 | MAPT (0.32) | MAPT | |
| SCHEMBL18633989 | 0.79 | NCF1 (0.39) | MAPTGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL24696328 | 0.77 | SIGMAR1 (0.44) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL14771563 | 0.77 | SIGMAR1 (0.34) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL11857523 | 0.76 | SIGMAR1 (0.42) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL185540 | 0.76 | SIGMAR1 (0.42) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL24064245 | 0.76 | SIGMAR1 (0.42) | SIGMAR1NOS3NOS1NOS2 | |
| SCHEMBL11857534 | 0.76 | SIGMAR1 (0.42) | SIGMAR1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | UNIVERSITY OF KANSAS (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | UNIVERSITY OF KANSAS (US) | 2019-01-24 | — | — | US | disclosed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9597674-B2 | Z-selective olefin metathesis catalysts and their synthetic procedure | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2017-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745386-B2 | Coumarin based HSP90 inhibitors with urea and ether substituents | HSP90B1, HSP90AA1, HSP90AB1 | MAPT 1230/4885SIGMAR1 913/4885NOS3 2631/4885 |
| US-20190023698-A1 | COUMARIN BASED HSP90 INHIBITORS WITH UREA AND ETHER SUBSTITUENTS | HSP90B1, HSP90AA1, HSP90AB1 | MAPT 1270/4885SIGMAR1 853/4885NOS3 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.